Coombes, R. Charles ; Hall, Emma 
; Gibson, Lorna J. ; Paridaens, Robert ; Jassem, Jacek ; Delozier, Thierry ; Jones, Stephen E. ; Alvarez, Isabel ; Bertelli, Gianfilippo ; Ortmann, Olaf ; Coates, Alan S. ; Bajetta, Emilio ; Dodwell, David ; Coleman, Robert E. ; Fallowfield, Lesley J. ; Mickiewicz, Elizabeth ; Andersen, Jorn ; Lønning, Per E. ; Cocconi, Giorgio ; Stewart, Alan ; Stuart, Nick ; Snowdon, Claire F. ; Carpentieri, Marina ; Massimini, Giorgio ; Bliss, Judith M.
; Gibson, Lorna J. ; Paridaens, Robert ; Jassem, Jacek ; Delozier, Thierry ; Jones, Stephen E. ; Alvarez, Isabel ; Bertelli, Gianfilippo ; Ortmann, Olaf ; Coates, Alan S. ; Bajetta, Emilio ; Dodwell, David ; Coleman, Robert E. ; Fallowfield, Lesley J. ; Mickiewicz, Elizabeth ; Andersen, Jorn ; Lønning, Per E. ; Cocconi, Giorgio ; Stewart, Alan ; Stuart, Nick ; Snowdon, Claire F. ; Carpentieri, Marina ; Massimini, Giorgio ; Bliss, Judith M. 
Zusammenfassung
BACKGROUND: Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse. METHODS: We conducted a double-blind, randomized trial to test whether, after two to three years of tamoxifen therapy, switching to exemestane was more effective than ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric